First 18F-Labeled Tracer Suitable for Routine Clinical Imaging of sst Receptor-Expressing Tumors Using Positron Emission Tomography

Purpose: Despite excellent radionuclide characteristics, no 18F-labeled peptides are available for quantitative peptide receptor mapping using positron emission tomography (PET) so far, mainly due to time-consuming multistep radiosyntheses with limited overall yields. A newly developed two-step chemoselective conjugation method allows rapid and high-yield [18F]fluorination of peptides via oxime formation and was applied for the synthesis of new 18F-labeled carbohydrated Tyr3-octreotate (TOCA) analogs with optimized pharmacokinetics suitable for clinical routine somatostatin-receptor (sst) imaging. Experimental Design:18F-labeled glucose (Gluc-S-) and cellobiose (Cel-S-) derivatives of aminooxy-functionalized TOCA were synthesized via oxime formation with 4-[18F]fluorobenzaldehyde ([18F]FBOA-peptides). Both the in vitro internalization profile of Gluc-S-Dpr([18F]FBOA)TOCA and Cel-S-Dpr([18F]FBOA)TOCA in hsst2-expressing Chinese hamster ovary cells (dual tracer protocol) and their biodistribution in AR42J tumor-bearing mice were investigated and compared with two [18F]fluoropropionylated ([18F]FP) analogs, Gluc-Lys([18F]FP)TOCA and Gluc-S-Dpr([18F]FP)TOCA. Results: In contrast to [18F]FP-labeling (3 h), chemo-selective [18F]FBOA-formation (50 min) afforded the respective radiopeptides in high yields (65–85%). In vitro, Gluc-S-Dpr([18F]FBOA)TOCA and Cel-S-Dpr([18F]FBOA)-TOCA showed high internalization (139 ± 2 and 163 ± 8 of the reference [125I]Tyr3-octreotide, respectively), which was reflected by high tumor accumulation in vivo [21.8 ± 1.4 and 24.0 ± 2.5% of injected dose/g (1 h), respectively]. How-ever, only Cel-S-Dpr([18F]FBOA)TOCA and Gluc-S-Dpr([18F]FP)TOCA (tumor: 15.1 ± 1.5% of injected dose/g) with its very low accumulation in all of the nontarget organs showed improved tumor:organ ratios compared with Gluc-Lys([18F]FP)TOCA. For Cel-S-Dpr([18F]FBOA)TOCA,tumor:organ ratios (1 h) were 42:1, 27:1, 15:1, 3:1, and 208:1 for blood, liver, intestine, kidney, and muscle, respectively. Conclusion: Due to the fast and high-yield chemoselective radiofluorination strategy and to its excellent pharmacokinetics, Cel-S-Dpr([18F]FBOA)TOCA represents the first tracer suitable for routine clinical application in PET somatostatin receptor imaging.

[1]  Horst Kessler,et al.  Multimeric cyclic RGD peptides as potential tools for tumor targeting: solid-phase peptide synthesis and chemoselective oxime ligation. , 2003, Chemistry.

[2]  H. Friedman,et al.  Specific and high-level targeting of radiolabeled octreotide analogues to human medulloblastoma xenografts. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  L. Kvols,et al.  86Y-DOTA0-d-Phe1-Tyr3-octreotide (SMT487)—a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[4]  M. Zalutsky,et al.  N-succinimidyl 3-[(131)I]iodo-4-phosphonomethylbenzoate ([(131)I]SIPMB), a negatively charged substituent-bearing acylation agent for the radioiodination of peptides and mAbs. , 2003, Bioconjugate chemistry.

[5]  E. Krenning,et al.  Tissue distribution of octreotide binding receptors in normal mice and strains prone to autoimmunity , 2002, Nuclear medicine communications.

[6]  M. Schwaiger,et al.  Improvement of pharmacokinetics of radioiodinated Tyr(3)-octreotide by conjugation with carbohydrates. , 2002, Bioconjugate chemistry.

[7]  S. Stone-Elander,et al.  In vivo biodistribution and pharmacokinetics of (18)F-labeled human C-peptide: evaluation in monkeys using positron emission tomography. , 2002, Life sciences.

[8]  J. Reubi,et al.  NODAGATOC, a new chelator-coupled somatostatin analogue labeled with [67/68Ga] and [111In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors. , 2002, Bioconjugate chemistry.

[9]  C. Beglinger,et al.  Neuroendocrine tumor targeting: Study of novel gallium‐labeled somatostatin radiopeptides in a rat pancreatic tumor model , 2002, International journal of cancer.

[10]  I. Shin,et al.  Solution-phase synthesis of aminooxy peptoids in the C to N and N to C directions. , 2002, Organic letters.

[11]  S. Larson,et al.  Ga-66 labeled somatostatin analogue DOTA-DPhe1-Tyr3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors. , 2002, Nuclear medicine and biology.

[12]  Vladimir Tolmachev,et al.  Targeting peptides and positron emission tomography. , 2002, Biopolymers.

[13]  M. Scheunemann,et al.  Biodistribution and catabolism of (18)F-labeled neurotensin(8-13) analogs. , 2002, Nuclear medicine and biology.

[14]  M. Schwaiger,et al.  PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel 18F-labelled, carbohydrated analogue of octreotide , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[15]  P. Schöffski,et al.  Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: preliminary data , 2001, European Journal of Nuclear Medicine.

[16]  H. Saji,et al.  Effect of molecular charges on renal uptake of 111In-DTPA-conjugated peptides. , 2001, Nuclear medicine and biology.

[17]  U. Haberkorn,et al.  PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  Okarvi Sm,et al.  Recent progress in fluorine-18 labelled peptide radiopharmaceuticals , 2001 .

[19]  Sibylle Ziegler,et al.  Noninvasive Imaging of αvβ3 Integrin Expression Using 18F-labeled RGD-containing Glycopeptide and Positron Emission Tomography , 2001 .

[20]  R Laforest,et al.  64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[21]  M Schwaiger,et al.  Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[22]  M. Schwaiger,et al.  Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. , 2001, Cancer research.

[23]  S. Okarvi,et al.  Recent progress in fluorine-18 labelled peptide radiopharmaceuticals , 2001, European Journal of Nuclear Medicine.

[24]  M. Schwaiger,et al.  Comparison of radioiodinated TOC, TOCA and Mtr-TOCA: the effect of carbohydration on the pharmacokinetics , 2001, European Journal of Nuclear Medicine and Molecular Imaging.

[25]  A. Delmas,et al.  Identification of by-products from an orthogonal peptide ligation by oxime bonds using mass spectrometry and tandem mass spectrometry. , 2000, Rapid communications in mass spectrometry : RCM.

[26]  J. Reubi,et al.  Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use , 2000, European Journal of Nuclear Medicine.

[27]  C. Beglinger,et al.  Preclinical comparison in AR4-2J tumor-bearing mice of four radiolabeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-somatostatin analogs for tumor diagnosis and internal radiotherapy. , 2000, Endocrinology.

[28]  A. Bogni,et al.  A new, convenient method for the preparation of 4-[18F]fluorobenzyl halides. , 2000, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[29]  P. Cutler,et al.  Radiotherapy and dosimetry of 64Cu-TETA-Tyr3-octreotate in a somatostatin receptor-positive, tumor-bearing rat model. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  C. Beglinger,et al.  Differential regulation of somatostatin receptor type 2 (sst 2) expression in AR4-2J tumor cells implanted into mice during octreotide treatment. , 1999, Cancer research.

[31]  J. Lewis,et al.  In vitro and in vivo evaluation of 64Cu-TETA-Tyr3-octreotate. A new somatostatin analog with improved target tissue uptake. , 1999, Nuclear medicine and biology.

[32]  J. Lewis,et al.  Comparison of four 64Cu-labeled somatostatin analogues in vitro and in a tumor-bearing rat model: evaluation of new derivatives for positron emission tomography imaging and targeted radiotherapy. , 1999, Journal of medicinal chemistry.

[33]  H. Herzog,et al.  Uptake kinetics of the somatostatin receptor ligand [86Y]DOTA-dPhe1-Tyr3-octreotide ([86Y]SMT487) using positron emission tomography in non-human primates and calculation of radiation doses of the 90Y-labelled analogue , 1999, European Journal of Nuclear Medicine.

[34]  E. Krenning,et al.  Internalization of [DOTA degrees,125I-Tyr3]Octreotide by somatostatin receptor-positive cells in vitro and in vivo: implications for somatostatin receptor-targeted radio-guided surgery. , 1999, Proceedings of the Association of American Physicians.

[35]  J. Edwardson,et al.  Fates of endocytosed somatostatin sst2 receptors and associated agonists. , 1998, The Biochemical journal.

[36]  H. Saji,et al.  Renal metabolism of 111In-DTPA-D-Phe1-octreotide in vivo. , 1998, Bioconjugate chemistry.

[37]  J. Kraus,et al.  Alternative promoter usage and tissue specific expression of the mouse somatostatin receptor 2 gene , 1998, FEBS letters.

[38]  N. Bodor,et al.  Erratum: Octanol‐Water partition of nonzwitterionic peptides: Predictive power of a molecular size‐based model. Proteins 30:86–99, 1998 , 1998 .

[39]  E P Krenning,et al.  Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. , 1998, Cancer research.

[40]  David M. Goldenberg,et al.  Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations , 1998, European Journal of Nuclear Medicine.

[41]  P Buchwald,et al.  Octanol–water partition of nonzwitterionic peptides: Predictive power of a molecular size‐based model , 1998, Proteins.

[42]  H. Herzog,et al.  PET-pharmacokinetics of 18F-octreotide: a comparison with 67Ga-DFO- and 86Y-DTPA-octreotide. , 1997, Nuclear medicine and biology.

[43]  M. T. Stephenson,et al.  Indium-111-diethylenetriaminepentaacetic acid-octreotide is delivered in vivo to pancreatic, tumor cell, renal, and hepatocyte lysosomes. , 1997, Cancer research.

[44]  U. Kumar,et al.  Agonist-dependent regulation of cloned human somatostatin receptor types 1-5 (hSSTR1-5): subtype selective internalization or upregulation. , 1996, Endocrinology.

[45]  T. Visser,et al.  Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[46]  K. Hamacher,et al.  A comparative study of N.C.A. fluorine-18 labeling of proteins via acylation and photochemical conjugation. , 1996, Nuclear medicine and biology.

[47]  S. Lamberts,et al.  Internalization of the radioiodinated somatostatin analog [125I-Tyr3]octreotide by mouse and human pituitary tumor cells: increase by unlabeled octreotide. , 1995, Endocrinology.

[48]  H. Wester,et al.  (2-[18F]fluoropropionyl-(D)phe1)-octreotide, a potential radiopharmaceutical for quantitative somatostatin receptor imaging with PET: synthesis, radiolabeling, in vitro validation and biodistribution in mice. , 1994, Nuclear medicine and biology.

[49]  J. Kihlberg,et al.  Solid-phase synthesis and conformational studies of glycosylated derivatives of helper-T-cell immunogenic peptides from hen-egg lysozyme. , 1993, Carbohydrate research.

[50]  F. Buchegger,et al.  Site-specific conjugation of a radioiodinated phenethylamine derivative to a monoclonal antibody results in increased radioactivity localization in tumor. , 1993, Journal of medicinal chemistry.

[51]  G. Fricker,et al.  SDZ CO 611: a highly potent glycated analog of somatostatin with improved oral activity. , 1993, Life sciences.

[52]  M. Zalutsky,et al.  Labeling proteins with fluorine-18 using N-succinimidyl 4-[18F]fluorobenzoate. , 1992, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

[53]  J. Kihlberg,et al.  Building blocks for glycopeptide synthesis: glycosylation of 3-mercaptopropionic acid and Fmoc amino acids with unprotected carboxyl groups , 1991 .

[54]  Evon M. O. Abu-Taieh,et al.  Comparative study , 2003, BMJ : British Medical Journal.

[55]  N. Vaysse,et al.  Functional somatostatin receptors on a rat pancreatic acinar cell line. , 1988, The American journal of physiology.

[56]  H. Gottlieb,et al.  Studies in sugar chemistry. 2. A simple method for O-deacylation of polyacylated sugars , 1986 .

[57]  W. Funcke.  13C-NMR-Untersuchungen an Mutarotationsgemischen C-6- und C-4- sowie C-6-modifizierter Amadoriverbindungen , 1978 .

[58]  J. Carberry,et al.  A STUDY OF THE KINETICS OF THE REACTION BETWEEN NITROGEN DIOXIDE AND ALCOHOLS , 1953 .

[59]  E. Bergmann,et al.  774. Studies on organic fluorine compounds. Part I. Some esters of monofluoroacetic acid and related compounds , 1953 .